| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | STX11 |
| Uniprot No | O75558 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-287aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMKDRLA ELLDLSKQYD QQFPDGDDEF DSPHEDIVFE TDHILESLYR DIRDIQDENQ LLVADVKRLG KQNARFLTSM RRLSSIKRDT NSIAKAIKAR GEVIHCKLRA MKELSEAAEA QHGPHSAVAR ISRAQYNALT LTFQRAMHDY NQAEMKQRDN CKIRIQRQLE IMGKEVSGDQ IEDMFEQGKW DVFSENLLAD VKGARAALNE IESRHRELLR LESRIRDVHE LFLQMAVLVE KQADTLNVIE LNVQKTVDYT GQAKAQVRKA VQYEEKNPCR TLCCFCCPCL K |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于STX11重组蛋白的模拟参考文献示例(基于领域内典型研究方向，可能非真实存在)：
---
1. **文献名称**: *"Recombinant STX11 Restores Cytolytic Granule Exocytosis in FHL4 Patient Cells"*
**作者**: Zhang L, et al.
**摘要**: 研究通过重组表达人源STX11蛋白，证明其可恢复家族性噬血细胞性淋巴组织细胞增多症(FHL4)患者T细胞的细胞毒性颗粒胞吐功能，揭示了STX11在免疫突触形成中的关键作用。
2. **文献名称**: *"Structural and Functional Analysis of STX11-Munc18-2 Complex in Vesicle Trafficking"*
**作者**: Müller A, et al.
**摘要**: 利用重组STX11与Munc18-2蛋白进行体外结合实验，解析了二者互作的结构基础，阐明了该复合物在调控细胞内囊泡运输中的分子机制。
3. **文献名称**: *"Expression and Purification of Active Recombinant STX11 in Insect Cells"*
**作者**: Kim S, Park JH
**摘要**: 报道了一种在杆状病毒-昆虫细胞系统中高效表达可溶性STX11重组蛋白的方法，并通过体外脂质体融合实验验证其功能活性，为SNARE蛋白的功能研究提供工具。
4. **文献名称**: *"STX11 Mutation Screening and Functional Rescue by Recombinant Protein in FHL4 Models"*
**作者**: Gomez GA, et al.
**摘要**: 开发了重组STX11蛋白递送系统，成功挽救FHL4小鼠模型的免疫缺陷表型，证实了STX11在淋巴细胞毒性中的必要性。
---
**注意**：以上文献为模拟示例，实际研究中建议通过数据库(如PubMed、Web of Science)以关键词“STX11 recombinant”“Syntaxin 11 expression”等检索真实文献。已知真实研究中，STX11常与Munc18-2及FHL4相关，可参考以下真实作者的研究方向：
- Zur Stadt U, et al. 对FHL4中STX11突变的早期描述。
- Côte M, et al. 对STX11与Munc18-2互作机制的探索。
**Background of STX11 Recombinant Protein**
Syntaxin 11 (STX11) is a member of the syntaxin family of SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins, which play critical roles in intracellular membrane trafficking and vesicle fusion. STX11 is notably involved in immune regulation, particularly in cytotoxic granule exocytosis within natural killer (NK) cells and T lymphocytes. Unlike other syntaxins, STX11 lacks a transmembrane domain, anchoring instead via palmitoylation or protein interactions, and it localizes to cytoplasmic vesicles or plasma membranes.
Genetic mutations in *STX11* are linked to familial hemophagocytic lymphohistiocytosis type 4 (FHL4), a life-threatening immune disorder characterized by defective cytotoxic lymphocyte function and uncontrolled inflammation. This association underscores STX11’s essential role in immune cell communication and pathogen clearance.
Recombinant STX11 protein is produced in vitro using expression systems (e.g., *E. coli* or mammalian cells) to study its structure, interactions, and pathogenic mechanisms. Its purified form enables researchers to investigate binding partners (e.g., Munc18-2. SNAP23) and the functional impact of FHL4-associated mutations. Additionally, recombinant STX11 serves as a tool for developing therapeutic strategies, diagnostic assays, or targeted drug screening for immune disorders. Challenges in its production include maintaining proper folding and post-translational modifications critical for activity.
Current research focuses on elucidating STX11’s role in vesicle trafficking dysregulation and its potential as a biomarker or therapeutic target. The recombinant protein remains pivotal for advancing understanding of immune pathologies and precision medicine approaches.
×
